Columnar lined (Barrett's) esophagus: future perspectives.
Columnar lined esophagus (CLE) or Barrett's esophagus is the precursor for esophageal adenocarcinoma. Future advances in understanding and management of this condition as well as improving the quality of care of CLE patients depends on answering essential questions. It is important to standardize the criteria for CLE definition. The rapid increase in incidence of CLE and adenocarcinoma raises serious concerns that the current management of gastroesophageal reflux disease (GERD) needs reassessment. The risk factors that determine who will and will not develop CLE are as yet undetermined. There is a need to develop a clinical risk stratification tool, which will help in determining who should be screened. The impact of elimination of GERD on the natural history of CLE is one important area for future research. The benefit of surveillance strategies remains unproven and the ideal endoscopic frequency, protocols and markers of cancer risk are unknown. Dysplasia may not provide the gold standard marker of cancer risk because of some inherited problems. A better technique than the current endoscopic pinch biopsy protocol is needed. To overcome the limitations of histological markers, many other markers of cancer risk needs to be developed and validated. The key question as to whether cancer risk is actually reduced by the new ablation modalities remains unanswered. The natural history of dysplasia and its management needs to be clarified. Although many questions have to be answered, it seems, however, that at least some answers exist, and these and proposals for answering some of these questions are underlined throughout this review.
Bani-Hani
Kamal E
KE
Department of Surgery, King Abdullah University Hospital, Faculty of Medicine, Jordan University of Science and Technology, Irbid, Jordan. banihani60@yahoo.com
Bani-Hani
Bayan K
BK
D000230:Adenocarcinoma / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D001471:Barrett Esophagus / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D015415:Biomarkers; D003937:Diagnosis, Differential; D004938:Esophageal Neoplasms / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control; D005762:Gastroenterology / Q000639:trends; D005764:Gastroesophageal Reflux / Q000150:complications / Q000175:diagnosis; D006801:Humans; D015994:Incidence; D007422:Intestines / Q000473:pathology; D008679:Metaplasia; D011230:Precancerous Conditions / Q000150:complications / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D012307:Risk Factors
D015415:Biomarkers